Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
Global Partners Declares First-Quarter 2026 Cash Distribution of $0.7650 on Common Units
08:30am, Thursday, 30'th Apr 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
Lilly's stock rallies as sales of GLP-1 drugs nearly double
06:58am, Thursday, 30'th Apr 2026
Sales of Mounjaro and Zepbound both beat expectations
Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
06:51am, Thursday, 30'th Apr 2026
Eli Lilly raised its annual profit forecast and posted better-than-expected first quarter on Thursday, on steady demand for its weight-loss and diabetes drugs Zepbound and Mounjaro, in its first
Best Income Stocks to Buy for April 29th
05:31am, Wednesday, 29'th Apr 2026
GLP, BP and EGO made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 29th, 2026.
New Strong Buy Stocks for April 29th
05:25am, Wednesday, 29'th Apr 2026
DVN, EGO, GLP, MUSA and BP have been added to the Zacks Rank #1 (Strong Buy) List on April 29th, 2026.
Best Value Stocks to Buy for April 29th
04:51am, Wednesday, 29'th Apr 2026
BP, DVN and GLP made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 29th, 2026.
Filing seeks to extend EL-22 myostatin-engineered probiotic platform into pharmaceutical applications for muscle preservation in patients on GLP-1 receptor agonists and across multiple muscle-wasting
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means
09:55am, Tuesday, 28'th Apr 2026
GLP-1 seller Hims & Hers Health NYSE: HIMS has seen significant volatility in its stock price as of late. Notably, despite seeing a 41% single-day surge in early March, HIMS remains down nearly 10% in
Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful met
GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
10:15am, Monday, 27'th Apr 2026
Novo Nordisk's (NYSE:NVO) Wegovy pill, the oral version of its blockbuster GLP-1 (glucagon-like peptide-1) weight-loss treatment, is tracking at roughly twice the prescription volumes of Eli Lilly's c
3 Top Refining & Marketing MLPs to Buy for Growth Ahead
09:31am, Friday, 24'th Apr 2026
Following a careful analysis of the Zacks Oil and Gas - Refining & Marketing MLP industry. we advise buying three stocks: GLP, SPH and CAPL.
Global Partners LP to Host First-Quarter 2026 Financial Results Conference Call on May 8, 2026
08:30am, Friday, 24'th Apr 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its first-quarter 2026 financial results before th
GLP-compliant program covering rodents, non-rodents, and primates will define safety, MTD and safe dose ranges, targeting weight loss and TIIDM Novel Ibogaine formulation development for mental health
West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
01:42pm, Thursday, 23'rd Apr 2026
West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the company's first-quarter 2026 earnings surpassed analyst estimates.
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
09:05am, Thursday, 23'rd Apr 2026
Contracts signed for Animal Study #2: GLP-1-A26-2 Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (N
